Thanigaimalai Pillaiyar

Dr. Thanigaimalai Pillaiyar

Pharmaceutical institute, Department of Pharmaceutical and Medicinal Chemistry, University of Bonn, An der Immenburg 4, D-53121 Bonn, Germany
+1
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2017 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
MMManoj Manickam
Manoj Manickam
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
Melanogenesis is a process to synthesize melanin, which is a primary responsible for the pigmentation of human skin, eye and hair. Although numerous enzymatic catalyzed and chemical reactions are involved in melanogenesis process, the enzymes such as tyrosinase and tyrosinase-related protein-1 (TRP-1) and TRP-2 played a major role in melanin synthesis. Specifically, tyrosinase is a key enzyme, which catalyzes a rate-limiting step of the melanin synthesis, and the downregulation of tyrosinase is the most prominent approach for the development of melanogenesis inhibitors. Therefore, numerous inhibitors that target tyrosinase have been developed in recent years. The review focuses on the recent discovery of tyrosinase inhibitors that are directly involved in the inhibition of tyrosinase catalytic activity and functionality from all sources, including laboratory synthetic methods, natural products, virtual screening and structure-based molecular docking studies.

15 February 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
MMManoj Manickam
Manoj Manickam
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
YHYoshio Hayashi
Yoshio Hayashi
SJSang-Hun Jung
Sang-Hun Jung
Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CLpro, has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection. Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications). This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003–2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening. We describe here mainly peptidomimetic and small molecule inhibitors of SARS-CoV 3CLpro. Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.

1 April 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
SMSangeetha Meenakshisundaram
Sangeetha Meenakshisundaram
MMManoj Manickam
Manoj Manickam

15 May 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
VNVigneshwaran Namasivayam
Vigneshwaran Namasivayam
MMManoj Manickam
Manoj Manickam
SJSang-Hun Jung
Sang-Hun Jung

1 December 2017 in Cellular Signalling
Verified
Journal Article
Closed access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
MMManoj Manickam
Manoj Manickam
SJSang-Hun Jung
Sang-Hun Jung

1 February 2017 in Drug Discovery Today
Verified
Journal Article
Closed access
Thanigaimalai PillaiyarThanigaimalai Pillaiyar
Thanigaimalai Pillaiyar
MMManoj Manickam
Manoj Manickam
SJSang-Hun Jung
Sang-Hun Jung